Trandolapril 4 mg Tablet Under Fasting Conditions

NCT ID: NCT00840632

Last Updated: 2024-08-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-10-31
• Study Completion Date: 2004-11-30

Brief Summary

The objective of this study is to compare the rate and extent of absorption of trandolapril from a test formulation of Trandolapril 4 mg Tablets versus the reference Mavik® 4 mg Tablets under fasting conditions.

Detailed Description

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA bioequivalence statistical methods

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Trandolapril

Trandolapril 4 mg Tablet (test) dosed in first period followed by Mavik® 4 mg Tablet (reference) dosed in second period

Group Type: EXPERIMENTAL

Trandolapril 4 mg Tablets

Intervention Type: DRUG

1 x 4 mg, single-dose fasting

Mavik®

Mavik® 4 mg Tablet (reference) dosed in first period followed by Trandolapril 4 mg Tablet (test) dosed in second period

Group Type: ACTIVE_COMPARATOR

Mavik® 4 mg Tablets

Intervention Type: DRUG

1 x 4 mg, single-dose fasting

Interventions

Trandolapril 4 mg Tablets

1 x 4 mg, single-dose fasting

Intervention Type: DRUG

Mavik® 4 mg Tablets

1 x 4 mg, single-dose fasting

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Non-smoking male or female with a minimum age of 18 years (i.e. non-smoker or non-tobacco user for at least 90 days prior to pre-study medical screening).
• Body Mass Index (BMI = weight/height2) greater than or equal to 19.0 kg.m2 and less than or equal to 30.0 kg/m2.
• Normal findings in the physical examination, 12-lead ECG and vital signs (blood pressure between 100-140/60-90 mmHg, heart rate between 50-100 beats/min, temperature between 35.8°C and 37.5°C).
• Negative for drugs of abuse, nicotine, hepatitis B-surface antigen, hepatitis C and HIV, and for female subjects, pregnancy (serum β-CG).
• No clinical laboratory values outside of the acceptable range as defined by BCR, unless the Principal Investigator decides they are not clinically significant.
• Female subjects who are surgically sterile for at least six months or post-menopausal for at least one year, or who will avoid pregnancy prior to the study, during the study and up until one month after the end of the study.

Exclusion Criteria

• Known history of hypersensitivity to trandolapril (e.g. Mavik®) other ACE inhibitors such as captopril, benazepril, enalapril, lisinopril, ramipril, quinapril, or cilazapril or angiotensin receptor agonists such as losartan, candesartan, eprosartan, irbesartan, telmisartan, or valsartan.
• Known history or presence of cardiac, pulmonary, gastrointestinal, endocrine, musculoskeletal, neurological, hematological, liver or kidney disease, unless judged not clinically significant by the Principal Investigator or medical designate.
• Known history or presence of food allergies, or any condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
• Any clinically significant illness during the last four weeks prior to entry into this study.
• Presence of any significant physical or organ abnormality.
• Any subject with a history of drug abuse.
• Any history or evidence of psychiatric or psychological disease (including depression) unless deemed not clinically significant by the Principal Investigator, or medical designate.
• Use of any prescription medication within 14 days preceding entry into this study.
• Use of over the counter (OTC) medication within seven days preceding entry into this study (except for spermicidal/barrier contraceptive products).
• Female subjects: use of contraceptives (oral, transdermal, implant, Mirena® IUD) within 30 days prior to drug administration or a depot injection of progestogen drug (e.g. Depo-Provera®) within one year prior to drug administration.
• Female subjects: presence of pregnancy or lactation.
• Any subject who has had blood drawn within 56 days preceding this study, taken during the conduct of any clinical study at a facility other than BCR, or within the lockout period specified by a previous study conducted at BCR.
• Participation in a clinical trial with an investigational drug within 30 days preceding this study.
• Any subject who has donated blood within 56 days preceding this study.
• Any subject who has participated as a plasma donor in a plasmapheresis program within seven days preceding this study.
• Significant or recent history of asthma (after 12 years of age).
• Any subject with a recent (less than one year) history of alcohol abuse.
• Known history of frequent headaches or migraines.
• Known history of hereditary or idiopathic angioedema.
• Any history of severe allergic reaction (including drugs, food, insect bites, environmental allergens).
• Intolerance to venipuncture.
• Any clinically significant surgery within 4 weeks prior to the administration of the study medication.
• Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of inducers: barbiturates, carbamazepine, phenytoine, glucocorticoids, omeprazole,; examples of inhibitors: antidepressant (SSRI), cimetidine, diltiazem, macrolides, imidazoles, neuroleptics, verapamil, fluoroquinolones, antihistamines) within 30 days prior to administration of the study medication.
• Difficulty swallowing study medication.
• Difficulty fasting or consuming standard meals.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Teva Pharmaceuticals USA

INDUSTRY

Sponsor Role: lead

Principal Investigators

Paul Y Tam, M.D.

Role: PRINCIPAL_INVESTIGATOR

Biovail

Locations

Biovail Contract Research

Toronto, Ontario, Canada

Countries

Canada

Other Identifiers

2977

Identifier Type: -

Identifier Source: org_study_id